CN101918000B - 嘌呤衍生物在制备药物中的用途 - Google Patents

嘌呤衍生物在制备药物中的用途 Download PDF

Info

Publication number
CN101918000B
CN101918000B CN2008801067270A CN200880106727A CN101918000B CN 101918000 B CN101918000 B CN 101918000B CN 2008801067270 A CN2008801067270 A CN 2008801067270A CN 200880106727 A CN200880106727 A CN 200880106727A CN 101918000 B CN101918000 B CN 101918000B
Authority
CN
China
Prior art keywords
formula
compound
ester
series
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2008801067270A
Other languages
English (en)
Chinese (zh)
Other versions
CN101918000A (zh
Inventor
L·梅耶
K·贝塔耶布
H·加隆斯
N·欧玛塔
C·博修
K·莱斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Rennes 1
Universite Paris Descartes
Univerdite de Bretagne Occidentale
CHU DE BREST
Original Assignee
Universite de Rennes 1
Universite Paris Descartes
Univerdite de Bretagne Occidentale
CHU DE BREST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Rennes 1, Universite Paris Descartes, Univerdite de Bretagne Occidentale, CHU DE BREST filed Critical Universite de Rennes 1
Publication of CN101918000A publication Critical patent/CN101918000A/zh
Application granted granted Critical
Publication of CN101918000B publication Critical patent/CN101918000B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2008801067270A 2007-09-12 2008-09-12 嘌呤衍生物在制备药物中的用途 Expired - Fee Related CN101918000B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0706390A FR2920776B1 (fr) 2007-09-12 2007-09-12 Utilisation de derives de purine pour la fabrication d'un medicament
FR0706390 2007-09-12
PCT/FR2008/001278 WO2009068761A2 (fr) 2007-09-12 2008-09-12 Utilisation de derives de purine pour la fabrication d'un medicament

Publications (2)

Publication Number Publication Date
CN101918000A CN101918000A (zh) 2010-12-15
CN101918000B true CN101918000B (zh) 2012-11-21

Family

ID=39382006

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801067270A Expired - Fee Related CN101918000B (zh) 2007-09-12 2008-09-12 嘌呤衍生物在制备药物中的用途

Country Status (13)

Country Link
US (1) US8431583B2 (enExample)
EP (1) EP2187889B1 (enExample)
JP (1) JP5485893B2 (enExample)
KR (1) KR20100075908A (enExample)
CN (1) CN101918000B (enExample)
BR (1) BRPI0816810A2 (enExample)
CA (1) CA2699590A1 (enExample)
DK (1) DK2187889T3 (enExample)
ES (1) ES2444419T3 (enExample)
FR (1) FR2920776B1 (enExample)
MX (1) MX2010002680A (enExample)
RU (1) RU2500400C2 (enExample)
WO (1) WO2009068761A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
WO2013130461A1 (en) * 2012-02-29 2013-09-06 The Scripps Research Institute Wee1 degradation inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022805A2 (en) * 2001-09-11 2003-03-20 Albany Molecular Research, Inc. Heterocycle substituted purines as antiproliferative agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6969720B2 (en) * 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
DE60205376T2 (de) * 2001-06-27 2006-04-06 Cyclacel Ltd. 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
GB0315259D0 (en) 2003-06-30 2003-08-06 Cyclacel Ltd Use
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003022805A2 (en) * 2001-09-11 2003-03-20 Albany Molecular Research, Inc. Heterocycle substituted purines as antiproliferative agents

Also Published As

Publication number Publication date
ES2444419T3 (es) 2014-02-25
KR20100075908A (ko) 2010-07-05
DK2187889T3 (da) 2014-02-03
BRPI0816810A2 (pt) 2017-05-16
RU2500400C2 (ru) 2013-12-10
CA2699590A1 (fr) 2009-06-04
WO2009068761A3 (fr) 2010-01-07
RU2010108505A (ru) 2011-10-20
FR2920776A1 (fr) 2009-03-13
EP2187889A2 (fr) 2010-05-26
CN101918000A (zh) 2010-12-15
US20100311768A1 (en) 2010-12-09
EP2187889B1 (fr) 2013-11-06
JP2010539146A (ja) 2010-12-16
JP5485893B2 (ja) 2014-05-07
MX2010002680A (es) 2010-08-26
FR2920776B1 (fr) 2012-09-28
WO2009068761A2 (fr) 2009-06-04
US8431583B2 (en) 2013-04-30

Similar Documents

Publication Publication Date Title
TWI758623B (zh) Ｂｃｌ-２抑制劑與ＢＴＫ抑制劑的組合產品在預防和/或治療疾病中的用途
JP7030656B2 (ja) ＰＤＥ４阻害剤とＰＩ３δ阻害剤または二重ＰＩ３δ－γキナーゼ阻害剤とを含有する薬学的組成物
KR20160017047A (ko) 이중 선택적 pi3 델타 및 감마 키나아제 억제제
CN103370068A (zh) Jak-2 介导的病症的治疗
JP2006516110A (ja) プロテインキナーゼのインヒビターとして有用なチアゾール化合物
EP3858833B1 (en) Aminonorbornane derivative and manufacture method thereof and use thereof
WO2012120195A1 (en) New pyridazinone and pyridone compounds
US20240033266A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN101918000B (zh) 嘌呤衍生物在制备药物中的用途
JP2025000907A (ja) 筋肉量及び酸化的代謝を増加させるための組成物及び方法
CA3030232A1 (en) Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines
CN106714842B (zh) 包含双重PI3K δ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物
US20150265608A1 (en) Compounds for Treating Rac-GTPase Mediated Disorder
US11427574B2 (en) Compounds for treating Rac-GTPase mediated disorder
JP2014515026A (ja) アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
JP2024544019A (ja) 化合物
WO2019246427A1 (en) Crystalline forms of pyridinone-containing tricyclic compounds and methods of preparing and using same
WO2020051230A1 (en) Amorphous pharmaceutical compositions and uses thereof
CN1990462A (zh) 琥珀酰肼类化合物及其组合物在制备治疗抗白血病药物方面的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121121

Termination date: 20180912

CF01 Termination of patent right due to non-payment of annual fee